{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:54:56Z","timestamp":1791327296108,"version":"4.3.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in Europe but post-transplantation Cyclophosphamide (PTCy) is an emerging alternative. We analyzed outcomes of rATG (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097725) vs. PTCy (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091039) prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood alloSCT from 10\/10 antigen-matched unrelated donors (MUD) between January 2018 and June 2021 in the EBMT database. The provided\n                    <jats:italic>P<\/jats:italic>\n                    -values and hazard ratios (HR) are derived from multivariate analysis. Two years after alloSCT, NRM in the PTCy group was 12.1% vs. 16.4% in the rATG group;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016; HR 0.72. Relapse was less frequent after PTCy vs. rATG (22.8% vs. 26.6%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.046; HR 0.87). Overall survival after PTCy was higher (73.1% vs. 65.9%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001, HR 0.82). Progression free survival was better after PTCy vs. rATG (64.9% vs. 57.2%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001, HR 0.83). The incidence of chronic GVHD was lower after PTCy (28.4% vs. rATG 31.4%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012; HR 0.77), whereas the incidence and severity of acute GVHD were not significantly different. GVHD-free relapse-free survival was significantly higher in the PTCy arm compared to the rATG arm (2\u2009y incidence: 51% vs. 45%; HR: 0.86 [95% CI 0.75\u20130.99],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.035). In the absence of evidence from randomized controlled trials, our findings support a preference for the use of PTCy in adult recipients of peripheral blood alloSCTs from MUD.\n                  <\/jats:p>","DOI":"10.1038\/s41375-024-02225-7","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:05:09Z","timestamp":1711548309000},"page":"1156-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouad","family":"Abouqateb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Peczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Boreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-6021","authenticated-orcid":false,"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-8239","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-1735","authenticated-orcid":false,"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"2225_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","volume":"107","author":"HT Greinix","year":"2022","unstructured":"Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica. 2022;107:1054\u201363. https:\/\/doi.org\/10.3324\/haematol.2020.265769.","journal-title":"Haematologica"},{"key":"2225_CR2","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u2013e167. https:\/\/doi.org\/10.1016\/S2352-3026(19)30256-X.","journal-title":"Lancet Haematol"},{"key":"2225_CR3","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, randomized, double-blind, phase iii clinical trial of Anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35:4003\u201311. https:\/\/doi.org\/10.1200\/JCO.2017.75.8177.","journal-title":"J Clin Oncol"},{"key":"2225_CR4","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2215943","journal-title":"N Engl J Med"},{"key":"2225_CR5","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bolanos-Meade","year":"2019","unstructured":"Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132\u2013e143. https:\/\/doi.org\/10.1016\/S2352-3026(18)30221-7.","journal-title":"Lancet Haematol"},{"key":"2225_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41409-020-0970-x","volume":"56","author":"E Brissot","year":"2021","unstructured":"Brissot E, Lapobin M, Labussiere H. Post-transplantation cyclophosphamide versus antithymocyte globulin after Ric regimen Allo-Hct: first analysis of a prospective randomized multicenter trial in recipients of 10\/10 matched donors. Bone Marrow Transpl. 2021;56:12\u201313.","journal-title":"Bone Marrow Transpl"},{"key":"2225_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18620\/ctt-1866-8836-2020-9-1-53-59","volume":"9","author":"E Morozova","year":"2020","unstructured":"Morozova E, Moiseev I, Vlasova Y. Randomized study between thymoglobulin and posttransplant cyclophosphamide in patients with chronic myeloid neoplasms undergoing unrelated allogeneic stem cell transplantation. Cell Ther Transpl. 2020;9:53\u20139.","journal-title":"Cell Ther Transpl"},{"key":"2225_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1071268","volume":"13","author":"L Tang","year":"2023","unstructured":"Tang L, Liu Z, Li T, Dong T, Wu Q, Niu T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: a systematic review and meta-analysis. Front Oncol. 2023;13:1071268 https:\/\/doi.org\/10.3389\/fonc.2023.1071268.","journal-title":"Front Oncol"},{"key":"2225_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2225_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317. https:\/\/doi.org\/10.1016\/0002-9343(80)90380-0.","journal-title":"Am J Med"},{"key":"2225_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2225_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002959","volume":"13","author":"P Mu\u00f1iz","year":"2022","unstructured":"Mu\u00f1iz P, Andr\u00e9s-Zayas C, Carbonell D, Chicano M, Bail\u00e9n R, Oarbeascoa G, et al. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation. Front Immunol. 2022;13:1002959.","journal-title":"Front Immunol"},{"key":"2225_CR13","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","volume":"26","author":"A Ruggeri","year":"2020","unstructured":"Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JL, et al. Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:1915\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2225_CR14","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Investig. 2019;129:2357\u201373.","journal-title":"J Clin Investig"},{"key":"2225_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2021-146997","volume":"138","author":"MJ McAdams","year":"2021","unstructured":"McAdams MJ, Hyder M, Dimitrova D, Sadler JL, McKeown C, Steinberg SM, et al. Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood. 2021;138:101.","journal-title":"Blood"},{"key":"2225_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","volume":"58","author":"R Dul\u00e9ry","year":"2023","unstructured":"Dul\u00e9ry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transpl. 2023;58:1215\u201322.","journal-title":"Bone Marrow Transpl"},{"key":"2225_CR17","doi-asserted-by":"publisher","unstructured":"Dulery R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Rev. 2023:101080. https:\/\/doi.org\/10.1016\/j.blre.2023.101080.","DOI":"10.1016\/j.blre.2023.101080"},{"key":"2225_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12185-021-03280-x","volume":"115","author":"TT Chen","year":"2022","unstructured":"Chen TT, Lin CC, Lo WJ, Hsieh CY, Lien MY, Lin CH, et al. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies. Int J Hematol. 2022;115:525\u201333. https:\/\/doi.org\/10.1007\/s12185-021-03280-x.","journal-title":"Int J Hematol"},{"key":"2225_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1140217","volume":"10","author":"WH Gao","year":"2023","unstructured":"Gao WH, Zhu JY, Wang LN, Wan M, Wang L, Devillier R, et al. Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: a single center analysis. Front Med. 2023;10:1140217 https:\/\/doi.org\/10.3389\/fmed.2023.1140217.","journal-title":"Front Med"},{"key":"2225_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"W Zhang","year":"2023","unstructured":"Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, et al. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: a multicentre, randomized controlled clinical trial. Br J Haematol. 2023;200:210\u201321. https:\/\/doi.org\/10.1111\/bjh.18483.","journal-title":"Br J Haematol"},{"key":"2225_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41409-017-0053-9","volume":"53","author":"U Deotare","year":"2018","unstructured":"Deotare U, Atenafu EG, Loach D, Michelis FV, Kim DD, Thyagu S, et al. Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. Bone Marrow Transpl. 2018;53:361\u20135. https:\/\/doi.org\/10.1038\/s41409-017-0053-9.","journal-title":"Bone Marrow Transpl"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02225-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T06:08:33Z","timestamp":1714975713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02225-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OP has received honoraria or travel support from Gilead, Jazz, MSD, Novartis, Pfizer and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution. She has also received non-financial support from Gilead, Pfizer, the EBMT (European Society for Blood and Marrow transplantation) and the CIBMTR (Center for International Bone Marrow Transplantation Research). IM received honoraria or travel support from Novartis, Sanofi, SOBI, Takeda. CCL received honoraria or travel support from Gilead\/Kite and Therakos. Consulting fees for advisory board from Gilead\/Kite, Nektar Therapeutics. FB participated to AB and received speaker fees from NEOVII and SANOFI. PD reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi, Novartis, Riemser; speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Novartis, Riemser, Roche; research support from Riemser (all to institution). RZ received speaker fees from Novartis, Incytem Neovii, MNK and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the EBMT review board. Patients had to sign an informed consent document that permitted sharing of clinical data according to national rules.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}